ImmunoGen CEO: Solving Cancer’s Access Challenge With Data, Differentiation And A Big Dose of Bipartisanship
Executive Summary
ImmunoGen CEO Mark Enyedy, a leading proponent of targeted ADC oncologics, explains to In Vivo how high risk – and dogged resilience – are central features of a challenging innovative landscape in cancer today. Despite some recent setbacks on the road to commercialization, science will continue to transform, bolstered by the industry's financial commitments; revolutionary new data sources, validated by patient-centered outcomes; and that persistent human intangible called hope.
You may also be interested in...
Viz.ai: Precision Targeting Of Every Patient’s Medical “Moment Of Truth”
Viz.ai is making artificial intelligence real and ready with an algorithm-based detection and diagnostics platform that is beating the clinical clock in fighting stroke. The start-up is now focused on positioning its joined-up AI software as standard-setter for broader patient engagement with big pharma on everything from participation in clinical trials to launching the next generation of high-touch specialty medicines.
Lilly's Bridge Builder, From Indiana To South Africa
Rising Leader Christopher Jon Stokes of Eli Lilly explains how some early life lessons in the restorative powers of community has guided a distinctive career path marked by engaging widely, understanding intuitively and listening actively, all in the pursuit of forging productive human connections that strive to “meet the moment” for patients.
Africa’s Geographer Of Genes
Nigerian start-up 54gene seeks to be the first private sector enterprise bent on applying Africa’s rich genetic heritage to solve the world’s most intractable diseases – ethically, without boundaries, for all.